<DOC>
	<DOCNO>NCT01056835</DOCNO>
	<brief_summary>The purpose study evaluate effect Prostaglandin I2 analogue use development chronic allograft nephropathy change allograft function prevalent renal transplant recipient</brief_summary>
	<brief_title>Effects PGI2 Analogue Use Development Chronic Allograft Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>prevalent renal transplant recipient 2 year transplantation history acute rejection stable renal function history biopsyproven chronic allograft nephropathy history biopsyproven CNI nephrotoxicity history biopsyproven clinical acute rejection unstable trough level CNI extremely low level CNI bleeding tendency ( + ) pregnancy pregnantwilling anticoagulation ( + ) antiplatelet agent ( + ) significant comorbidity ( + ) : Acute coronary syndrome , pneumonia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>